Bristol-Myers Squibb Co vs General Motors Company — how do they compare? Bristol-Myers Squibb Co trades at $63.59 (market cap $129.94B), while General Motors Company trades at $89.19 (market cap $78.40B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | GM | |
|---|---|---|
Market Cap | $129.94B | $78.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $90.30 |
52-Week Low | $42.60 | $54.16 |
Enterprise Value | $163.92B | $181.38B |
Dividend Yield | 3.96% | 0.81% |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →